FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995562313> ?p ?o ?g. }

• W2995562313 abstract "Abstract Background Current guidelines for the management of bronchiectasis (BE) highlight the lack of evidence to recommend mucoactive agents, such as hypertonic saline (HTS) and carbocisteine, to aid sputum removal as part of standard care. We hypothesise that mucoactive agents (HTS or carbocisteine, or a combination) are effective in reducing exacerbations over a 52-week period, compared to usual care. Methods This is a 52-week, 2 × 2 factorial, randomized, open-label trial to determine the clinical effectiveness and cost effectiveness of HTS 6% and carbocisteine for airway clearance versus usual care - the Clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care (CLEAR) trial. Patients will be randomised to (1) standard care and twice-daily nebulised HTS (6%), (2) standard care and carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day), (3) standard care and combination of twice-daily nebulised HTS and carbocisteine, or (4) standard care. The primary outcome is the mean number of exacerbations over 52 weeks. Key inclusion criteria are as follows: adults with a diagnosis of BE on computed tomography, BE as the primary respiratory diagnosis, and two or more pulmonary exacerbations in the last year requiring antibiotics and production of daily sputum. Discussion This trial’s pragmatic research design avoids the significant costs associated with double-blind trials whilst optimising rigour in other areas of trial delivery. The CLEAR trial will provide evidence as to whether HTS, carbocisteine or both are effective and cost effective for patients with BE. Trial registration EudraCT number: 2017-000664-14 (first entered in the database on 20 October 2017). ISRCTN.com, ISRCTN89040295 . Registered on 6 July/2018. Funder: National Institute for Health Research, Health Technology Assessment Programme (15/100/01). Sponsor: Belfast Health and Social Care Trust. Ethics Reference Number: 17/NE/0339. Protocol version: v3.0 Final_14052018." @default.
• W2995562313 created "2019-12-26" @default.
• W2995562313 creator A5000252949 @default.
• W2995562313 creator A5004507036 @default.
• W2995562313 creator A5016119932 @default.
• W2995562313 creator A5020601451 @default.
• W2995562313 creator A5024552865 @default.
• W2995562313 creator A5027367120 @default.
• W2995562313 creator A5034835364 @default.
• W2995562313 creator A5041103166 @default.
• W2995562313 creator A5045273192 @default.
• W2995562313 creator A5052118474 @default.
• W2995562313 creator A5056681502 @default.
• W2995562313 creator A5061029083 @default.
• W2995562313 creator A5062366073 @default.
• W2995562313 creator A5068789733 @default.
• W2995562313 creator A5070372650 @default.
• W2995562313 creator A5073009982 @default.
• W2995562313 creator A5082181496 @default.
• W2995562313 creator A5082960100 @default.
• W2995562313 creator A5084570512 @default.
• W2995562313 creator A5086402495 @default.
• W2995562313 creator A5090239373 @default.
• W2995562313 date "2019-12-01" @default.
• W2995562313 modified "2023-10-02" @default.
• W2995562313 title "A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial" @default.
• W2995562313 cites W1952635484 @default.
• W2995562313 cites W1990166011 @default.
• W2995562313 cites W2034353280 @default.
• W2995562313 cites W2036134364 @default.
• W2995562313 cites W2045833618 @default.
• W2995562313 cites W2101936405 @default.
• W2995562313 cites W2102330462 @default.
• W2995562313 cites W2103204694 @default.
• W2995562313 cites W2111407500 @default.
• W2995562313 cites W2118417086 @default.
• W2995562313 cites W2138268920 @default.
• W2995562313 cites W2139243564 @default.
• W2995562313 cites W2144086845 @default.
• W2995562313 cites W2144755740 @default.
• W2995562313 cites W2145836734 @default.
• W2995562313 cites W2147083782 @default.
• W2995562313 cites W2151355567 @default.
• W2995562313 cites W2165617076 @default.
• W2995562313 cites W2195693652 @default.
• W2995562313 cites W2274288325 @default.
• W2995562313 cites W2276030464 @default.
• W2995562313 cites W2623856550 @default.
• W2995562313 cites W2752498201 @default.
• W2995562313 cites W2788768006 @default.
• W2995562313 cites W2806270040 @default.
• W2995562313 cites W2889573530 @default.
• W2995562313 cites W2891945008 @default.
• W2995562313 cites W2905363638 @default.
• W2995562313 cites W2916004124 @default.
• W2995562313 cites W4210297421 @default.
• W2995562313 doi "https://doi.org/10.1186/s13063-019-3766-9" @default.
• W2995562313 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6921594" @default.
• W2995562313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31856887" @default.
• W2995562313 hasPublicationYear "2019" @default.
• W2995562313 type Work @default.
• W2995562313 sameAs 2995562313 @default.
• W2995562313 citedByCount "5" @default.
• W2995562313 countsByYear W29955623132020 @default.
• W2995562313 countsByYear W29955623132021 @default.
• W2995562313 countsByYear W29955623132022 @default.
• W2995562313 countsByYear W29955623132023 @default.
• W2995562313 crossrefType "journal-article" @default.
• W2995562313 hasAuthorship W2995562313A5000252949 @default.
• W2995562313 hasAuthorship W2995562313A5004507036 @default.
• W2995562313 hasAuthorship W2995562313A5016119932 @default.
• W2995562313 hasAuthorship W2995562313A5020601451 @default.
• W2995562313 hasAuthorship W2995562313A5024552865 @default.
• W2995562313 hasAuthorship W2995562313A5027367120 @default.
• W2995562313 hasAuthorship W2995562313A5034835364 @default.
• W2995562313 hasAuthorship W2995562313A5041103166 @default.
• W2995562313 hasAuthorship W2995562313A5045273192 @default.
• W2995562313 hasAuthorship W2995562313A5052118474 @default.
• W2995562313 hasAuthorship W2995562313A5056681502 @default.
• W2995562313 hasAuthorship W2995562313A5061029083 @default.
• W2995562313 hasAuthorship W2995562313A5062366073 @default.
• W2995562313 hasAuthorship W2995562313A5068789733 @default.
• W2995562313 hasAuthorship W2995562313A5070372650 @default.
• W2995562313 hasAuthorship W2995562313A5073009982 @default.
• W2995562313 hasAuthorship W2995562313A5082181496 @default.
• W2995562313 hasAuthorship W2995562313A5082960100 @default.
• W2995562313 hasAuthorship W2995562313A5084570512 @default.
• W2995562313 hasAuthorship W2995562313A5086402495 @default.
• W2995562313 hasAuthorship W2995562313A5090239373 @default.
• W2995562313 hasBestOaLocation W29955623131 @default.
• W2995562313 hasConcept C112930515 @default.
• W2995562313 hasConcept C126322002 @default.
• W2995562313 hasConcept C142724271 @default.
• W2995562313 hasConcept C168563851 @default.
• W2995562313 hasConcept C177713679 @default.
• W2995562313 hasConcept C2776301714 @default.
• W2995562313 hasConcept C2781069245 @default.
• W2995562313 hasConcept C3017567848 @default.
• W2995562313 hasConcept C3019080777 @default.
• W2995562313 hasConcept C42219234 @default.

• next